Dan Leggate

I joined Storm Therapeutics in August 2016 where my focus has been on developing assays to measure the activity of RNA-modifying enzymes. Prior to this, I have worked at companies including Cellzome, BioFocus and several small start-ups. My involvement in drug discovery spans over 15 years, mostly in the area of assay development and HTS, working across a range of novel and established target classes. I am a biochemist by training, obtaining an MA and PhD from the University of Cambridge.